In a newly developed model of bone cancer pain, a secreted ‘decoy’ tumor necrosis factor receptor protein, osteoprotegerin, blocks neurochemical signals in the spinal cord and pain associated with osteolytic metastases (pages 521–528).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mercadante, S. Malignant bone pain: pathophysiology and treatment. Pain 69, 1–18 (1997).
Portenoy, R.K., Payne, D. & Jacobsen, P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81, 129– 134 (1999).
Woolf, C.J. et al. Towards a mechanism based classification of pain. Pain 77, 227–228 ( 1998).
Schwei, M. J. et al. Neurochemical and cellular reorganization in the spinal cord in a murine model of bone cancer pain. J. Neurosci. 19, 10886–10897 (1999).
Honore, P. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med. 6, 521–528 ( 2000).
Mundy, G.R. Bone resorbtion and turnover in health and disease. Bone 8 (suppl), S1–S6. ( 1987).
Kong, Y.Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 401, 304–308 (1999).
Hsu, H. et al., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540– 3545. (1999).
Bucay N. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260–1268 (1998).
Yaksh, T.L. et al. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc. Natl. Acad. Sci. USA 96, 7680–7686. ( 1999).
Fulfaro, F. et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78 , 157–169 (1998).
Bekker, P.J. et al. Osteoprotegerin (OPG) has potent and sustained anti-resorbtive activity in postmenopausal women. J. Bone Mineral Res. 14, S180 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thompson, S., Tonge, D. Bone cancer gain without the pain. Nat Med 6, 504–505 (2000). https://doi.org/10.1038/74977
Issue Date:
DOI: https://doi.org/10.1038/74977
